|
Originally published In Press as doi:10.1074/jbc.M204117200 on September 4, 2002
J. Biol. Chem., Vol. 277, Issue 47, 45172-45180, November 22, 2002
Differential Splicing Generates Tvl-1/RFXANK Isoforms with
Different Functions*
Santasabuj
Das §,
Jun-Hsiang
Lin ¶,
Joseph
Papamatheakis ,
Yuri
Sykulev , and
Philip N.
Tsichlis **
From the Kimmel Cancer Center, Thomas Jefferson
University, Philadelphia, Pennsylvania 19107 and the Foundation
for Research and Technology, Institute of Molecular Biology and
Biotechnology, Heraklion, 711 10 Crete, Greece
Earlier studies have shown that Tvl-1
gives rise to at least two differentially spliced mRNAs, one of
which (Tvl-S) encodes a protein that lacks amino acids
91-112. DNA binding of RFX complexes assembled in the presence of
Tvl-S is impaired. As a result, Tvl-S does not support the expression
of Class II major histocompatibility complex (MHC) genes. Here,
we show that the reason Tvl-S is inactive as a transcriptional
regulator of Class II MHC genes is that the RFX complexes assembled in
the presence of Tvl-S are unstable. Additionally, we show that
interferon- , which induces Class II MHC gene expression in
293 cells, promotes a shift in the splicing pattern of RFXANK/Tvl-1
toward the transcriptionally active Tvl-L isoform, suggesting that
differential splicing of Tvl-1 is a signal-regulated process. Finally,
we show that Tvl-1 regulates the expression of non-MHC genes. One such
gene encodes the ephrin receptor EphA3. Since both Tvl-L and Tvl-S are
identical in their ability to induce the expression of EphA3, we
conclude that Tvl-1 regulates the expression of non-MHC genes by
RFX-independent mechanisms.
*
This work was supported by National Institutes of Health
Grant RO1 CA/GM80219 (to P. N. T.).The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address: Molecular Oncology Research Inst., Tufts-New
England Medical Center, 75 Kneeland St., Rm. 10025, Boston, MA 02111.
¶
Present address: Bristol-Meyers-Squibb Co., Pharmaceutical
Research Institute, P. O. Box 5400, Princeton, NJ 08543.
**
To whom correspondence should be addressed. Present address:
Molecular Oncology Research Inst., Tufts-New England Medical Center, 75 Kneeland St., 10th floor, Rm. 10025, Boston, MA 02111. Tel.:
617-636-6111; Fax: 617-636-6127; E-mail:
p_tsichlis@lifespan.org.
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Fang, X. Kong, P. Li, F. Fang, X. Wu, H. Bai, X. Qi, Q. Chen, and Y. Xu
RFXB and its splice variant RFXBSV mediate the antagonism between IFN{gamma} and TGF{beta} on COL1A2 transcription in vascular smooth muscle cells
Nucleic Acids Res.,
May 22, 2009;
(2009)
gkp398v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Xu, L. Wang, G. Buttice, P. K. Sengupta, and B. D. Smith
Interferon {gamma} Repression of Collagen (COL1A2) Transcription Is Mediated by the RFX5 Complex
J. Biol. Chem.,
December 5, 2003;
278(49):
49134 - 49144.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|